4,5-Diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-ylamine

ID: ALA260135

Chembl Id: CHEMBL260135

PubChem CID: 6263849

Max Phase: Preclinical

Molecular Formula: C17H13N5

Molecular Weight: 287.33

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12

Standard InChI:  InChI=1S/C17H13N5/c18-16-14-13(11-7-3-1-4-8-11)15(12-9-5-2-6-10-12)19-21-17(14)22-20-16/h1-10H,(H3,18,20,21,22)

Standard InChI Key:  NPHKXSDZIKFIRU-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA260135

   Pyrazolopyridazine 1a

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 287.33

Molecular Weight (Monoisotopic): 287.1171

AlogP: 3.27

#Rotatable Bonds: 2

Polar Surface Area: 80.48

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.42

CX Basic pKa: 3.04

CX LogP: 2.91

CX LogD: 2.91

Aromatic Rings: 4

Heavy Atoms: 22

QED Weighted: 0.59

Np Likeness Score: -0.60

References

1. Witherington J, Bordas V, Garland SL, Hickey DM, Ife RJ, Liddle J, Saunders M, Smith DG, Ward RW..  (2003)  5-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).,  13  (9): [PMID:12699759] [10.1016/s0960-894x(03)00134-3]

2. Witherington J, Bordas V, Haigh D, Hickey DM, Ife RJ, Rawlings AD, Slingsby BP, Smith DG, Ward RW..  (2003)  5-aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).,  13  (9): [PMID:12699760] [10.1016/s0960-894x(03)00135-5]

3. Witherington J, Bordas V, Gaiba A, Garton NS, Naylor A, Rawlings AD, Slingsby BP, Smith DG, Takle AK, Ward RW..  (2003)  6-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).,  13  (18): [PMID:12941332] [10.1016/s0960-894x(03)00645-0]

4. Witherington J, Bordas V, Gaiba A, Naylor A, Rawlings AD, Slingsby BP, Smith DG, Takle AK, Ward RW..  (2003)  6-heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3).,  13  (18): [PMID:12941333] [10.1016/s0960-894x(03)00646-2]

5. Braña MF, Cacho M, García ML, Mayoral EP, López B, de Pascual-Teresa B, Ramos A, Acero N, Llinares F, Muñoz-Mingarro D, Lozach O, Meijer L..  (2005)  Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.,  48  (22): [PMID:16250643] [10.1021/jm058013g]

6. Taha MO, Bustanji Y, Al-Ghussein MA, Mohammad M, Zalloum H, Al-Masri IM, Atallah N..  (2008)  Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.,  51  (7): [PMID:18324764] [10.1021/jm7009765]

7. Patel DS, Bharatam PV..  (2008)  Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies.,  43  (5): [PMID:17707953] [10.1016/j.ejmech.2007.06.016]

8. PubChem BioAssay data set, 

9. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

10. Maqbool M, Mobashir M, Hoda N..  (2016)  Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.,  107  [PMID:26562543] [10.1016/j.ejmech.2015.10.018]

11. Simon Townson and Suzanne Gokool. GlaxoSmithKline Published Kinase Inhibitor Set 2 Onchocerca lienalis Screening Data,  [10.6019/CHEMBL3988181]

Source

Source(4):

• Scientific Literature
• PubChem BioAssays
• AstraZeneca Deposited Data
• Published Kinase Inhibitor Set 2